Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells

被引:16
作者
Agatheeswaran, S. [1 ,3 ]
Pattnayak, N. C. [2 ,4 ]
Chakraborty, S. [1 ]
机构
[1] Inst Life Sci, Nalco Sq, Bhubaneswar, Odisha, India
[2] SCB Med Coll, Dept Clin Haematol, Cuttack, Odisha, India
[3] Lund Univ, Lund Stem Cell Ctr, Div Mol Med & Gene Therapy, S-22184 Lund, Sweden
[4] Lab Care & Diagnost, Cuttack, Odisha, India
来源
SCIENTIFIC REPORTS | 2016年 / 6卷
关键词
CHRONIC MYELOGENOUS LEUKEMIA; STEM-CELLS; CANCER; PROLIFERATION; EXPRESSION; IMATINIB; INHIBITION; MICRORNAS; INVASION; MIR-494;
D O I
10.1038/srep32493
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Chronic myeloid leukemia (CML) is maintained by leukemic stem cells (LSCs) which are resistant to the existing TKI therapy. Hence a better understanding of the CML LSCs is necessary to eradicate these cells and achieve complete cure. Using the miRNA-gene interaction networks from the CML lin(-) cells we identified a set of up/down-regulated miRNAs and corresponding target genes. Association studies (Pearson correlation) from the miRNA and gene expression data showed that miR-1469 and miR-1972 have significantly higher number of target genes, 75 and 50 respectively. We observed that miR-1972 induces G2-M cell cycle arrest and miR-1469 moderately arrested G1 cell cycle when overexpressed in KCL22 cells. We have earlier shown that a combination of imatinib and JAK inhibitor I can significantly bring down the proliferation of CML lineage negative cells. Here we observed that imatinib and JAK inhibitor I combination restored the expression pattern of the down-regulated miRNAs in primary CML lin(-) cells. Thus effective manipulation of the deregulated miRNAs can restore the miRNA-mRNA networks that can efficiently inhibit CML stem and progenitor cells and alleviate the disease.
引用
收藏
页数:9
相关论文
共 41 条
  • [1] Agatheeswaran S., 2014, BLOOD
  • [2] Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth
    Agirre, Xabier
    Jimenez-Velasco, Antonio
    San Jose-Eneriz, Edurne
    Garate, Leire
    Bandres, Eva
    Cordeu, Lucia
    Aparicio, Oscar
    Saez, Borja
    Navarro, German
    Vilas-Zornoza, Amaia
    Perez-Roger, Ignacio
    Garcia-Foncillas, Jesus
    Torres, Antonio
    Heiniger, Anabel
    Jose Calasanz, Maria
    Fortes, Puri
    Roman-Gomez, Jose
    Prosper, Felipe
    [J]. MOLECULAR CANCER RESEARCH, 2008, 6 (12) : 1830 - 1840
  • [3] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004)
    Bartel, David P.
    [J]. CELL, 2007, 131 (04) : 11 - 29
  • [4] Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
    Bhatia, R
    Holtz, M
    Niu, N
    Gray, R
    Snyder, DS
    Sawyers, CL
    Arber, DA
    Slovak, ML
    Forman, SJ
    [J]. BLOOD, 2003, 101 (12) : 4701 - 4707
  • [5] Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
    Casetti, Luana
    Martin-Lanneree, Severine
    Najjar, Imen
    Plo, Isabelle
    Auge, Sylvie
    Roy, Lydia
    Chomel, Jean-Claude
    Lauret, Evelyne
    Turhan, Ali G.
    Dusanter-Fourt, Isabelle
    [J]. CANCER RESEARCH, 2013, 73 (07) : 2052 - 2058
  • [6] RETRACTED: MiRNA-494 inhibits metastasis of cervical cancer through Pttg1 (Retracted article. See April, 2017)
    Chen, Bing
    Hou, Zhaohui
    Li, Chundong
    Tong, Ying
    [J]. TUMOR BIOLOGY, 2015, 36 (09) : 7143 - 7149
  • [7] MicroRNAs modulate hematopoietic lineage differentiation
    Chen, CZ
    Li, L
    Lodish, HF
    Bartel, DP
    [J]. SCIENCE, 2004, 303 (5654) : 83 - 86
  • [8] Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
    Corbin, Amie S.
    Agarwal, Anupriya
    Loriaux, Marc
    Cortes, Jorge
    Deininger, Michael W.
    Druker, Brian J.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (01) : 396 - 409
  • [9] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Druker, Brian J.
    Guilhot, Francois
    O'Brien, Stephen G.
    Gathmann, Insa
    Kantarjian, Hagop
    Gattermann, Norbert
    Deininger, Michael W. N.
    Silver, Richard T.
    Goldman, John M.
    Stone, Richard M.
    Cervantes, Francisco
    Hochhaus, Andreas
    Powell, Bayard L.
    Gabrilove, Janice L.
    Rousselot, Philippe
    Reiffers, Josy
    Cornelissen, Jan J.
    Hughes, Timothy
    Agis, Hermine
    Fischer, Thomas
    Verhoef, Gregor
    Shepherd, John
    Saglio, Giuseppe
    Gratwohl, Alois
    Nielsen, Johan L.
    Radich, Jerald P.
    Simonsson, Bengt
    Taylor, Kerry
    Baccarani, Michele
    So, Charlene
    Letvak, Laurie
    Larson, Richard A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) : 2408 - 2417
  • [10] miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts
    Eiring, Anna M.
    Harb, Jason G.
    Neviani, Paolo
    Garton, Christopher
    Oaks, Joshua J.
    Spizzo, Riccardo
    Liu, Shujun
    Schwind, Sebastian
    Santhanam, Ramasamy
    Hickey, Christopher J.
    Becker, Heiko
    Chandler, Jason C.
    Andino, Raul
    Cortes, Jorge
    Hokland, Peter
    Huettner, Claudia S.
    Bhatia, Ravi
    Roy, Denis C.
    Liebhaber, Stephen A.
    Caligiuri, Michael A.
    Marcucci, Guido
    Garzon, Ramiro
    Croce, Carlo M.
    Calin, George A.
    Perrotti, Danilo
    [J]. CELL, 2010, 140 (05) : 652 - 665